You searched for "oncology"

954 results found

In conversation with Sarika Nalagatla

We were delighted to catch up with Sarika Nalagatla, new Chair of the BAUS Section of Trainees (BSoT) about her life as a trainee urologist and plans for the association. Can you tell us a little bit about what led...

Anti-VEGF and PD-1 combinations in renal cell carcinoma

Over the past decade, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) have been central to treating renal cell carcinoma (RCC), with oncologists refining dosing strategies to balance treatment efficacy with quality of life (QoL). Recently, the introduction of...

Prostate Cancer Vaccine Research Launched in Surrey

In September 2025, The Prostate Project, a Guildford-based volunteer-led charity, will launch a £250,000 campaign to raise funds for a prostate cancer research project widely anticipated to be ‘game-changing’. Work has begun to develop a vaccine to prevent the return...

Sarcomatoid renal cell carcinoma

Renal cell carcinoma (RCC) represents 2-3% of all cancers [1]. It is an adenocarcinoma making up 85% of all renal malignancies. Sarcomatoid transformation is a microscopically identified feature of RCC accounting for 5% of all RCCs [2]. Known as sarcomatoid...

Management dilemma for very high-risk non–muscle-invasive bladder cancer

The European Association of Urology (EAU) guidelines recommend upfront radical cystectomy (RC) for very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC). However, real-world adoption is limited, as most patients are reluctant to undergo immediate bladder removal. The EAU 2021 risk model...

The Parnell Fund Bursary 2019

At the start of July 2019 applications for the Parnell Fund Bursary were opened to trainees, consultants and healthcare professionals across the United Kingdom with an interest in female, functional and neuro-urology. Rachel Barratt, who was awarded the Parnell Fund...

The impact of menopause on bladder symptoms

The menopause is a natural process of ageing when the ovaries completely stop producing reproductive hormones (oestrogen and other sex steroids), and there are no monthly periods for 12 consecutive months. It normally occurs between the ages of 45-55 years...

Focal therapy for prostate cancer – ready for prime time?

The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...

BAUS Annual Scientific Meeting 2024

Day 1 Toni Huw Mihailidis and Mriganka Mani Sinha Another year and another brilliant meeting in which urologists from the UK and around the globe assembled for a highly entertaining event. Day one kicked off with a topical and ever-pervasive...

In conversation with Professor Christopher Chapple

Professor Christopher Chappel. Prof Chapple, thank you for taking the time to chat with the Urology News team. Can we start by asking about your background and how you ended up in the field of urology? Early in my career...

Management of RHC in prostate cancer with selective embolisation and hyperbaric oxygen therapy

Prostate cancer is one of the most prevalent malignancies affecting men worldwide. Radiotherapy is a common treatment modality for localised and locally advanced prostate cancer. While radiotherapy can be effective, it may lead to complications such as radiation-induced haemorrhagic cystitis...

Urinary biomarkers for surveillance of non-muscle invasive bladder cancer

Bladder cancer (BC) is the ninth most common cancer worldwide with a yearly incidence of approximately 430,000 cases. There is a male predominance and it is the seventh most common cancer in men worldwide [1]. Non-muscle invasive bladder cancer (NMIBC)...